Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer said that Lipitor 80mg was more effective than simvastatin 20mg to 40mg in reducing the risk of multiple cardiovascular events in patients with a history of heart attacks in a comparative trial.
Subscribe to our email newsletter
The results from comparative trial were presented at the Annual Scientific Sessions of the American Heart Association.
All 8,888 patients enrolled in the trial had a prior heart attack, and 2,546 of them experienced at least one additional cardiovascular event after entering the trial. A new post-hoc analysis (planned after study closed) reported that 1,048 patients had a second cardiovascular event during the course of the trial. In those patients treated with Lipitor, there was a significant 24% reduction in relative risk of having that second event than those treated with simvastatin.
The analysis also found that 416 patients had a third event during the course of the trial. In those patients treated with Lipitor there was a significant 19% reduction in relative risk of having that third event compared to simvastatin. The overall results of this analysis are even more robust in patients who were more adherent to treatment.